Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Sumitomo Pharma Oncology, Inc. has presented updated preliminary data from a Phase 1/2 clinical study evaluating TP-3654 at the European Hematology Association 2023 Hybrid Congress. The investigational selective oral PIM1 kinase inhibitor is being tested in patients with myelofibrosis who were previously treated with or ineligible for JAK inhibitor therapy. Preliminary data showed spleen volume reduction and total symptom score improvement in relapsed/refractory myelofibrosis patients. Sumitomo Pharma Oncology, Inc.'s commitment remains to advance this program with additional clinical sites and contributing to the progress of potential treatment options that may improve outcomes for patients with myelofibrosis. The updated results of TP-3654 monotherapy in relapsed/refractory MF patients showed spleen volume reduction and total symptom score improvement. The drug was well-tolerated with no myelosuppressive treatment-related adverse events observed to date. TP-3654 alone and in combination with ruxolitinib also showed normalized WBC and neutrophil counts, reduced spleen size, and bone marrow fibrosis in murine models of myelofibrosis. Myelofibrosis is rare hematological malignancy that causes debilitating symptoms such as